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Engineering Department, Centre for International Manufacturing, Institute for Manufacturing, School of Technology, University of
Cambridge, Cambridge, UK
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Targeting a series of advanced manufacturing technology (AMT) ‘interventions’ provides the potential for signiﬁcant step
changes across the pharmaceutical value chain, from early stage ‘system discovery’ and clinical trials, through to novel
service supply models. This research explores future value network conﬁgurations which, when aligned with disruptive
shifts in technology (process and digital), may enable alternative routes to medicines production and the delivery of
additional value to ‘end-users’, i.e. patients and health care providers. We draw on a categorisation of AMTs that may
enable a shift from the traditional ‘batch’ and centralised manufacturing paradigm of ‘make-to-stock’, towards more
re-distributed ‘continuous’ manufacturing and ‘make-to-order’ models. Despite reported beneﬁts in the academic
literature (e.g. reduced footprints, improved quality, enhanced ﬂexibility and inventory savings), current adoption rates of
continuous technologies in this sector remain low (c. 5%). This paper presents new data sources, in our study of AMT
adoption in a global pharmaceutical context – assessing the barriers to implementation, and the pathways to delivering
future continuous manufacturing scenarios. Our ﬁndings capture the high level of disparity in viewpoints, highlighting
the uncertainties and transformational challenges ahead – in terms of opportunity areas, technological readiness and a
future vision for the sector, as a whole.
Keywords: continuous manufacturing; technology interventions; pharmaceutical value networks; reconﬁguration
opportunities; scenario assessment
1. Introduction
The pharmaceutical industry is undergoing a period of great change, reacting to the ‘patent cliff’, with fewer
blockbusters being launched, R&D productivity at record low levels and the requirement for more niche products to
serve new markets (Dixon et al. 2010). Many organisations are now actively reviewing their global footprints and
legacy supply chains, driven by, for example, growth in emerging markets, and questioning whether they have the
optimal architecture for manufacturing in the future (Harrington and Srai 2016). This highlights a particular problem
faced by the pharmaceutical sector – the very signiﬁcant uncertainty around which new molecules and products are
selected for development, and around clinical trial outcomes (Shah 2004). While the number of compounds in develop-
ment has increased by approximately 60% and total R&D expenditures have doubled over the past 10 years, the average
number of new drug entities approved each year has declined, with only one in 10 small molecules entering clinical
development expected to advance to full FDA approval (Hay et al. 2014). With estimates that average drug development
costs are now circa. $2600–2800M (Avorn, 2014) – an increase from averages of $800M in the early 2000s (DiMasi
2002; DiMasi, Hansen, and Grabowski 2003), it is growing more critical to balance risk and potential rewards, promote
faster development timelines, and to make better informed and earlier decisions on the pipeline (DiMasi, Grabowski,
and Hansen 2016).
The sector has a reputation for being conservative, compared to other related industries that have successfully
implemented sophisticated advanced manufacturing technologies (AMTs) that increase both process and product under-
standing (Saberi and Yusuff 2012; Rantanen and Khinast 2015). While identiﬁcation, selection, acquisition and imple-
mentation issues have been dominant topics to-date in AMT literature (Chan et al. 2001; Goyal and Grover 2012),
currents trends across the pharmaceutical industry – in accelerating innovative technology delivery, and establishing new
supply chains for medicines – can help address a key research gap of addressing the realities of modern manufacturing
environments (Farooq and O’Brien 2012). Here, the sector is looking to reconﬁgure value networks, moving towards
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smaller and more agile facilities, and associated end-to-end (E2E) supply chains, to support more dispersed and
globalised manufacturing models (Srai et al. 2015). However, limited attention has also been paid to the role of the
‘industrial system’ in ‘connecting’ technology developments to ﬁnal products, and how the design of the value network
needs to provide a link between the two (Harrington and Srai 2016). In this study, we draw on a categorisation of
AMTs (Gunawardana 2006) that may enable the shift from the traditional centralised and batch manufacturing paradigm
of ‘make-to-stock’, towards that of re-distributed ‘continuous’ manufacturing operations and ‘make-to-order’ models.
This research forms part of the on-going research agenda at the UK Centre for Innovative Manufacturing in
Continuous Manufacturing and Crystallisation. Research activities are targeting the adoption of continuous processing
technologies across the pharmaceutical industry (see Figure 1).
Speciﬁcally, this study focuses on AMTs, in the area of continuous crystallisation (CC), which is a critical unit oper-
ation in inﬂuencing the pharmacological properties and therapeutic efﬁcacy of a ﬁnal drug product (speciﬁcally respira-
tory and solid oral doses, which remain the prevalent dose forms today). Through design and control of this puriﬁcation
process, the aim is to promote improved crystal quality, in terms of targeted crystal size distribution, shape, polymorphic
form and purity, which is critical for the efﬁciency of downstream processes from the crystallisation step (ﬁltration and
drying) (Laird 2013). Such characteristics have a strong effect on the properties of the ﬁnal drug product, in terms of
dissolution, bioavailability, quality and shelf life (Variankaval, Cote, and Doherty 2008). We extend an analytical frame-
work – previously developed from a supply network perspective (Srai et al. 2015), using key literature and a series of
case examples to develop assessments involving a series of technology interventions. In the context of this paper, we
deﬁne ‘technology interventions’ as those which enable a signiﬁcant breakthrough in one or more research areas involv-
ing continuous crystallisation-based AMTs (Brown et al. 2014; Callahan and Ni 2014; McGlone et al. 2015), and pro-
cess analytical techniques (Powell et al. 2015, 2016). A series of workshop engagements involving industry and
academic experts were used to then test, reﬁne and validate the assessment framework and outputs.
The paper is structured as follows: ﬁrst we review the key literature on industrial system evolution, value networks
and reconﬁguration concepts, and perspectives on technology interventions, which inform our framework extension.
Section 3 summarises the investigative phase in developing a framework to assess technology interventions, involving a
combination of literature synthesis, case histories and secondary data, and an outline of framework testing/reﬁnement
using expert panels. Next, the methodology section outlines the research strategy and process/methods of data collection
and analysis. Section 5 demonstrates application of the four-step assessment framework, and criteria, in a pharmaceutical
context. Section 6 presents new sources, of AMT adoption in a global context, assessing the barriers to implementation,
and the pathways for delivering future continuous manufacturing scenarios. Finally, Section 7 presents conclusions,
study limitations and future research activities.
2. Literature review
This section is organised around the following themes relevant to the extension of a prototype framework, which have
emerged from literature on emerging technologies and industries, e.g.
Inputs
Molecular
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Crystal Growth
& Habit Control
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Production
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Processing
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Transport
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Figure 1. Continuous processing in the manufacture of pharmaceuticals – 10 focus areas targeting the adoption of AMTs (adapted
from CMAC 2014).
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• Industrial system evolution
• Value networks – reconﬁguration concepts
• Perspectives on technology interventions
Key insights, from this review, are then integrated to inform the development of a assessment framework to better
evaluate ‘technology interventions’ – from a value network perspective, in Section 3.
2.1 Industrial system evolution
Value networks and industrial systems continue to evolve, enabled by innovative manufacturing processes, and the
emergence of new technologies (Royal Academy of Engineering (RAE) 2012). Traditional approaches, to the study of
industrial systems in management literature, have often been developed on the assumption of ‘stable’ environments,
which do not adequately provide theoretical or practical guidance on how to effectively capture new and emerging mar-
ket opportunities (Zhang and Gregory 2011; Harrington and Srai 2012). Hence, a better understanding of the industrial
system in which a network operates (capturing context, resources, activities, processes, actors and interdependencies)
and an assessment of reconﬁguration opportunities, which may result from an AMT intervention, provide valuable
insights for both research and practice (Saberi and Yusuff 2012).
Within industrial systems, established ﬁrms are constantly reviewing and looking to reconﬁgure their legacy net-
works, leveraging existing capabilities where possible and creating advantages in terms of quality, ﬂexibility and lead
time, to support the emergence of new technologies and new operating or business models (Adner and Kapoor 2010).
However, optimising the conﬁguration of these fragmented networks is particularly challenging especially when there
are ‘multiple tiers’ of partner ﬁrms within an industrial system, spanning component and intermediate goods supply, pre-
senting a plethora of options on location and partnering models (Srai and Gregory 2008).
With the focus of this paper on reconﬁguring value networks driven by AMTs, two common ‘enablers’ were identi-
ﬁed that support the successful emergence of a new market, based on a radical technological intervention, and the ‘pro-
cess’ of commercialising a new technology. Firstly, the successful emergence of any new market depends largely on the
parallel development of a new supply or value chain to support commercialisation activities (Jacobides 2005; Sebastiao
and Golicic 2008; Harrington and Srai 2016). Secondly, ‘new market creation’ has been considered as the overall pro-
cess involving the coming together of a new network of stakeholders for the commercialisation of a new technology
(Zahra and Nielsen 2002; Voelpel, Leibold, and Tekie 2004; Sarasvathy and Dew 2005). Hence, a key criterion in ana-
lysing technology interventions and the subsequent effect on emerging and evolving industrial systems is the role that
the network of key institutional, industrial and supply network actors may play in the development of alternative busi-
ness models, effective supply network strategies and viable products and services.
2.2 Value networks – reconﬁguration concepts
For many decades, the drug product manufacturing model has been controlled by a regulatory framework – safeguarding
the quality of the ﬁnal product, by stringent process monitoring, testing of raw material, in-process material and end-
product characteristics – using batch-based operations (Rantanen and Khinast 2015; Srai et al. 2015). However, the sec-
tor needs to become more responsive to a changing environment, to devise new ways of providing patients with
improved health ‘outcomes’, at a fraction of today’s cost (Erhard et al. 2013).
In studies of the pharmaceutical sector, ‘value network’ terminology has often been more applicable, given the com-
plex interaction of clinical trials supply, primary (API) and secondary (drug product) manufacturing, and post-dosage
activities being increasingly spread across networks of specialised ﬁrms, who may also be geographically dispersed and
operating in mature and emerging economies (Edwards 2009). In terms of pharmaceutical value networks, new innova-
tive manufacturing processes (such as ‘continuous’), the emergence of specialist CMOs in ‘continuous’, new supply
chain partners (in distribution, logistics and the provision of digital technologies) are contributing to the need to recon-
ﬁgure the pharmaceutical landscape (Srai et al. 2015). One of the key drivers of ‘high value’ manufacturing is targeting
AMT solutions that present both tangible and intangible beneﬁts (Ariss, Raghunathan, and Kunnathar 2002). Previous
studies have shown that many enterprises commonly focus on too narrow a segment of the value network, to an extent
that the requirements of the ultimate ‘end-user’ (as opposed to the immediate customer for the product or technology)
are often not adequately recognised (Harrington and Srai 2016). Hence, critical linkages, between continuous crystallisa-
tion-based processing and other continuous technologies both upstream and downstream, and any associated implica-
tions for patients and government health providers should be considered. There may be unseen beneﬁts in a number of
areas; product variety, consistency and functionality, energy and resource efﬁciency, inventory and customisation
International Journal of Production Research 1473
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options, that may well contribute to a move towards more ‘continuous’ or ‘hybrid’ modes of processing becoming the
norm and not the exception.
2.3 Perspectives on technology interventions
Recent advances in novel technologies (in areas such as ‘continuous’ processing, printing, sensing and diagnostics) are
now creating the potential for signiﬁcant step changes across the health care sector, with opportunities ranging from clinical
trials, right through to the ‘end-user’ (Srai and Alinaghian 2013). In a recent review paper, examining the research and
manufacturing potential of inkjet ‘2-D’ printing, for the development of pharmaceutical drug products (Daly et al. 2015),
six ‘entry points’ and opportunity areas, in terms of research and speciﬁc technology ‘intervention’, were identiﬁed (see
Appendix 1). These ‘interventions’ included the potential of the AMT in enabling breakthroughs in rapid prototyping for
early stage ‘system’ discovery and clinical trials, instant and rapid changeovers within secondary processing, late customi-
sation – leading to increased ﬂexibility and service in terms of packaging/distribution, and the provision of personalised
‘dial-a-dose’ drug delivery to the patient. However, current adoption rates of continuous technologies within the
pharmaceutical sector remain low, with industrial exemplars of ‘continuous’ manufacturing only operating at pilot and/or
R&D lab scale capacities in many cases (Srai et al. 2015). While evidence exists that continuous processing delivers ﬁnan-
cial beneﬁts (mainly for single-purpose plants), studies and modelling have largely been focused at production and plant
levels, with the business case, in each case, lacking any formal E2E network assessment (Srai et al. 2015).
Implementing such innovations require organisations, and their extended global networks, to proactively adapt their
strategies to ensure an optimal ﬁt between changing competitive priorities and the development of critical support struc-
tures (Nair and Boulton 2008). To illustrate these opportunities, examples of radical value network reconﬁguration from
other sectors, as a result of the emergence of a new technology are brieﬂy outlined here:
• In vitro diagnostics (IVDs): here, new industrial actors have emerged such as IVD companies, specialist clinics
and laboratory equipment manufacturers to support the emergence of a technology. Subsequent disaggregation of
the value network has led to the reconﬁguration of information, material, and revenue ﬂows between industrial
actors, resulting in radically different patient-centric supply chain models, and the potential for novel business
models (Srai and Alinaghian 2013).
• Digital inkjet decoration and the industrial ceramics sector: a current drive to explore inkjet printing in many sec-
tors is largely due its very successful implementation as part of late-stage customisation tactics, involving variant
production at scale, in order to satisfy proliferation demands. Emergence has led to a revitalised industrial ceram-
ics sector in Europe, characterised by vastly reduced inventory levels, yet with enhanced ﬂexibility with respect to
near-market supply (Daly et al. 2015).
• The Internet, digitisation and the recorded music sector: historically dominated by ﬁve major record labels, a series
of innovations including the emergence of ﬁle compression techniques and the establishment of peer-to-peer (P2P)
networks have radically transformed value networks within the recorded music sector. Furthermore, e-business
models in this space, continue to open up opportunities for novel digital distribution channels involving music and
ﬁlm (Leyshon 2001).
In the context of the pharmaceutical sector, equivalent disruptions on a par with these three examples could enable
the adoption of technologies compatible with (i) the rapid scale-up of new niche drug products in smaller volumes, (ii)
novel delivery formats, with the option of late-stage personalisation and customisation and (iii) agile supply chains
designed to manage the potential of signiﬁcantly increased stock-keeping-units (SKUs).
The next section presents the development of an assessment framework to explore current and future conﬁgurations,
which when aligned with disruptive shifts in technology, may enable alternative routes to drug product production.
3. Literature synthesis – framework extension
An analytical framework – developed from a supply network perspective (Srai et al. 2015), was reﬁned using key litera-
ture across a series of research domains (see Figure 2). It is argued that it is critical to assess technology interventions
in terms of the E2E supply chain beneﬁts that breakthroughs may enable (e.g. time-to-patient; quality; inventory;
enhanced volume ﬂexibility and customisation; ﬁnancial impact; return on investment). In summary, this synthesis phase
examined:
• literature on emerging industry systems, in addition to eight technology-driven adoption/evolution case studies e.g.
product-service systems in Defence Aerospace; niche high-speciﬁcation production in Maritime; technologies for
1474 T.S. Harrington et al.
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sustainable built environments; technology platform development in Industrial Biotechnology; next-generation
technologies in Photovoltaics; e-Commerce driven ‘Last-Mile’ Logistics; e-mobility in Automotive, composite
materials in Civil Aerospace (Harrington and Srai 2012, 2016; Harrington et al. 2016). These were selected in
order to provide insights and inform the dimensions of analysis to consider in terms of technology adoption.
• literature on supply chain and value networks (conﬁguration concepts, ‘states’, ‘archetypes’) supported by in
excess of 40 network case studies and secondary data from the literature reﬂecting a number of diverse network
forms (data-sets capturing engineering, production, supply and service networks) was used to explore dimensions
of analysis as a basis to understanding the linkages between supply networks and technology interventions in a
Pharmaceutical context (Srai et al. 2015).
• Perspectives on ‘technology interventions’, examining previous studies on radical value network reconﬁgurations
in other sectors, and themes from the literature which included ‘stages’ of emergence, maturity descriptors, entry
points, opportunity areas and technology readiness (Daly et al. 2015; Harrington and Srai 2016).
The prototype framework was then tested and reﬁned through a series of workshops – capturing rich insights and
evidence from a variety of industrial practitioners on their speciﬁc AMT adoption and investment decisions, across a
range of pharmaceutical drug products. Outputs from the case study interviews, in combination with case-speciﬁc sec-
ondary data, were then used to reﬁne and ﬁnalise the assessment framework.
4. Methodology
This section presents an overview of the methodological approach used in his research paper. A mixed methodology
was employed, involving expert group input, followed by a multiple case study method. This multiple case study strat-
egy we adopt is in line with Yin’s deﬁnition (2009) of it being an empirical inquiry that investigates a contemporary
phenomenon both in-depth and within its real-life context. The approach is particularly appropriate here as this study
seeks to explore both practice-based (where the insights of key industrial stakeholders are critical) and emerging phe-
nomena when research and theory may be at an exploratory or formative stage (Eisenhardt and Graebner 2007; Yin
2009). The next section provides both details on the data collection process and methods, including information regard-
ing the qualitative investigation and case studies development (interviewees and timescales) to inform the development
of the technology intervention assessment framework.
Figure 2. Literature synthesis, expert workshops and development of assessment framework.
International Journal of Production Research 1475
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4.1 Data collection and analysis – process
This process involved a series of workshop-type engagements, targeting speciﬁc outputs (see Figure 2). Appendix 2 sets
outs the 58 expert informants, by role, contribution, and workshop linkages where applicable. The expert engagements
are summarised as follows:
(1) Royal Society of Chemistry workshop, on ‘redeﬁning the twenty-ﬁrst Century E2E pharmaceutical supply chain
through enhanced manufacturing ﬂexibility’ (Cambridge, March 2014). This initial stage involved 15 experts
across industry and academia, active in the area of continuous AMTs in pharma, sharing insights from speciﬁc
cases. Questionnaire outputs and a group discussion were then used to formulate a speciﬁc case review structure,
to identify synergies across cases, with focus centred on assessment of the barriers to future continuous manu-
facturing scenarios.
(2) Workshop on ‘Reconﬁguring pharmaceutical supply networks E2E through continuous manufacturing’, MIT
Continuous Manufacturing Symposium (Boston, May 2014). This stage involved eight experts, active in the area
of continuous AMTs, who shared insights on speciﬁc adoption and investment decisions, in assessing a series of
future continuous manufacturing scenarios for the global supply of Artemisinin-based Combination Therapies
(ACTs) – see Appendix 3.
(3) Workshop on ‘Pharmaceutical supply chains – setting the future research agenda’, Cambridge International Man-
ufacturing Symposium (Cambridge, September 2015). This stage involved 12 academics – specialising in supply
chain and global manufacturing domains – assessing a series of future continuous manufacturing scenarios,
involving novel technologies (in areas such as ‘continuous’ processing, printing, sensing and diagnosing).
(4) Leveraging access to 24 industrial partners, aligned with the Centre for Innovative Manufacturing in Continuous
Manufacturing and Crystallisation (CMAC), and project ‘ReMediES’ (Re-conﬁguring Medicines E2E Supply),
this workshop explored (a) what ﬁrms are using to select continuous manufacturing technologies to meet speciﬁc
E2E supply chain objectives and (b) linkages between in practice criteria and those derived from the literature
(Glasgow, March 2016).
(5) The ﬁnal validation workshop (Glasgow, June 2016) involved 12 experts, active in the area of continuous AMTs
in pharma, who shared insights on the technology assessment process for a speciﬁc in-depth application e.g.
CMAC continuous demonstrator, involving the manufacture of Paracetamol (APAP).
5. Assessment framework application
One of the main aims of this research is to highlight the management of AMTs in an increasingly globalised world. The
case studies (outlined in Section 3) informing framework extension, suggest signiﬁcantly enhanced product variety and/
or ﬂexibility to be key criteria in any future industry development. This together with the observed trend in the cases to
locate production closer to the end-user suggest future manufacturing will support small-scale distributed operations
where speed, and product/product-service customised solutions are more attractive value propositions, enabled by tech-
nology developments that provide these viable options.
In this section, the assessment framework is applied to demonstrate how one (or a combination of) continuous AMT
‘interventions’ may enable (a) reduced investment costs, through smaller production facilities with lower capital cost,
reduced overall plant footprint; (b) operating costs through lower catalyst and solvent use, and by minimising total reac-
tion times and (c) reducing inventory cost (less WIP inventory, with reduced material handling and transport).
A set of pre-screening criteria is ﬁrst used to identify the barriers to adopting alternative product-process technolo-
gies and business models. Using basic operational and societal data inputs to explore future trends (where implementa-
tion of ‘continuous’ may have a cost advantage or increase speed to market for an entity) and market requirements (in
terms of volume and product variety, affordability and unmet needs) the pre-screening stage facilitates the rapid analysis
(‘go’ vs. ‘no-go’) of whether an existing drug product or new molecule may be a viable candidate to investigate further
in terms of business case evaluation and AMT implementation. As outlined in Appendix 3, criteria should include:
• Therapy or disease area; patient population; treatment proﬁle; volumes (current, projected); basic ﬁnancials
(price, cost, revenues, margin); SKU mix; inventory; CapEx and quality/waste.
• In addition, to inform workﬂow development for rapid product assessment and continuous process selection, 10
critical ‘attributes’ – in terms of technology feasibility and chemistry that may also be assessed at this pre-screen-
ing stage – were identiﬁed. Focus here looks at complexity and area(s) of opportunity (in the context of ‘continu-
ous’ processing) with respect to molecule; polymorph; chirality; number of process steps; particle engineering;
kinetics; stability; bioavailability; ﬁnal dosage form and ease of scale-up/scale-out.
1476 T.S. Harrington et al.
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The next phase (stage 2) involves mapping the ‘current state’, in terms of technologies, unit operations and the
supply network. This leads to the identiﬁcation of critical ‘sub-systems’ (e.g. clinical trials, primary manufacturing,
secondary processing, packaging and distribution, and E2E supply) that may be affected by a shift to a future, more
continuous operating model. The ﬁrst current state mapping exercise identiﬁes those unit operations where an existing
batch production process may be ‘pre-disposed’ to a series of continuous technologies (in terms of current state and
future potential), namely, in synthesis; puriﬁcation; isolation; formulation and packaging. Here, the speciﬁc implications
of deﬁned continuous technology developments and readiness levels may be assessed (are certain routes to manufacture
pre-disposed to continuous processing? What alternative routes could be?).
An E2E network performance analysis is then used to deﬁne overall system metrics, and to evaluate the current state
conﬁguration and trade-offs being made. Current-state supply and value network mapping techniques are used to deﬁne
the existing sub-systems and the drivers/design factors that predominate in each sub-system. Associated impact variables
may then be scored, setting out the potential scale of the beneﬁt to patients, government health service providers and
industrial value network partners. Here, technology interventions are assessed in terms of 15 impact variables, namely:
inventory; lead-time supply; lead-time to market; scale-up (going into); volume ﬂexibility (mix and volume); process
control (including reliability and safety); quality (purity); yield; IP protection and extension (including issue of counter-
feits); cost (process, packaging and transport); investment cost (incorporating ﬁnancial impacts and return on invest-
ment); ﬁscal/tax; environmental impact; viability/adaptability and asset utilisation.
Future state process and network design scenarios, based on the emerging process technology options emerging from
stage 2 of the assessment framework and future industry trends are then assessed. Future state models, in the form of
value stream maps, generally explore several potential future states prior to a ﬁnal decision. Alternative states may be
based on emerging process and production technologies or AMTs that are still yet to be fully developed. In addition to
key industry reports, central to the decision-making process, is continued access to, and engagement with industry, in
order to assess future scenarios and the subsequent effect on the wider pharmaceutical landscape.
The research strategy we adopt enables cross-case analysis, in order to identify emerging patterns and other pharma-
ceutical drug products that may beneﬁt from similar value network design and reconﬁguration opportunities. The pro-
cess also facilitates the development of a series of ‘value network roadmaps’, which may be both generic sector
summaries, and product (category) speciﬁc. In the context of this research, these roadmaps may be deﬁned as a visual
representation, through time, of (disruptive) changes in ‘activities’ and ‘actors’ across the value chain, typically as a
result of multiple technological disruptions in process (i.e. T1 → T2 … Tn) and/or a network reconﬁguration of actors
(i.e. V1 → V2 … Vn), usually resulting in the emergence of new products (i.e. P1 → P2 … Pn) – see schematic repre-
sentation in Figure 3.
Within a pharmaceutical context, this stage can also support a performance assessment of several potential techno-
logical choices involving batch, continuous or hybrid routes, and involve a combination of:
(a) Providing a benchmark, in terms of potential yield and purity
(b) Evaluating various scenarios, which may involve alternative scale production footprints (dispersed, close-to-
market, low-scale and integrated plants) and
(c) Developing alternative supply models that might now be possible, due to technological advances in ordering or
replenishment.
In turn, architectural differences between batch, hybrid or continuous operations and associated implications for
up-stream and down-stream value network conﬁgurations, structures, processes, and systems may be assessed across a
series of product families. In practice, scenarios may depend on various disruptive inﬂuences that challenge the current
value network model and introduce a series of possible product or product-service models.
Finally, stage 4 integrates business context/viability and technology readiness inputs (from supporting technology
roadmaps) in order to evaluate value network reconﬁguration opportunities, and develop a case for transformation.
Inputs here include:
• Examining current and future states, in terms of key system metrics from stages 2 and 3
• Value propositions in making the transformation from a business context for key value network players, versus the
investments required (potential impact on revenue, margin and inventory reduction)
• Key economic evaluation criteria in terms of batch versus continuous, for example, direct ﬁxed capital, plant
throughput, manufacturing cost and unit production cost
• Finally, feasibility and timescales on speciﬁc AMT interventions
A series of emerging themes and insights from practitioners on the opportunities for technology-driven value net-
work reconﬁgurations in the pharmaceutical sector are now outlined in the following section.
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6. Results and implications
This section presents new sources in assessing the barriers to implementation, and the pathways for delivering future
continuous manufacturing scenarios, using the framework and scenarios set out in Section 5.
While there is collective agreement from industry and academia that the funding model for drug discovery involving small
molecules is becoming outdated and inefﬁcient, there is level of disparity of viewpoints when it comes to adoption of ‘contin-
uous’ manufacturing – in terms of opportunity areas, technological readiness levels and uncertainties and the transformation
challenges (including behaviours) that lay ahead within the sector. Table 1 summarises outputs from workshop 1 involving
industrial and academic experts who are actively involved in the areas of continuous ﬂow R&D and process-technology adop-
tion. Overcoming these barriers requires a coordinated and systematic approach when redesigning the entire value network.
Our research suggests that barriers may be real or perceived, and arise from combinations of socio-political, technical and reg-
ulatory factors. Content validity ratio (CVR) values were calculated1 and range between −1 (perfect disagreement) and +1
(perfect agreement), with CVR values above zero indicating that over half of panel members were in agreement. For a panel
size of 15, the critical level of agreement or disagreement (CVR critical) is +/−0.6 (Ayre and Scally 2014).
Second, in assessing pathways to future continuous manufacturing scenarios, critical to this is how best to manage
AMTs and best guide the selection of processes (continuous or batch). Identifying what adds value to the ultimate ‘end-
customer’ is not just a technical consideration, but also requires a change in mind-set. The future inﬂuence of the patient
was also cited as, potentially, the most disruptive factor across the entire industry. Hence, industry needs to design prod-
ucts and services based on patient needs, and not what an organisation ‘wants to make’. Key insights on how the sector
should approach ‘manufacturing in a new way’ to deliver value are summarised as follows:
• Technology interventions linked to E2E supply chain analysis should be a key deliverable in assessing any busi-
ness case (‘It’s more than just a ‘batch-to-continuous’ agenda’).
• While industry has committed to the principle of continuous processing, it may be better served to target ‘tactical’
AMT opportunities. Employing a phased approach, and scouting for opportunities where there are ‘low effort/high
yield’ opportunities, conﬁdence can be gained before applying more resources.
• It is argued that the industry, as a whole, doesn’t currently operate its batch processes at an optimum level. In the
future, how can the sector guarantee that continuous processes, enabled by AMTs, will operate any better? A key
consideration is to acknowledge that beneﬁts may be achievable without moving to a fully continuous route for some
products. For example, continuous, batch, or hybrid solutions may well drive agile supply chains of the future.
Figure 3. Reconﬁguring pharmaceutical value networks: targeted interventions (T1 → T2) changing the product and industrial
landscape (P1 and V1 → P2 and V2).
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For many of the emerging niche and high-cost candidates discussed as part of this study, scenarios often involve
exploring opportunities to reformulate in order to increase bioavailability. This opens up the potential to reduce
‘dosages’, hence, volumes are required for new formulations. There were cases where more combinations are likely to
be required in the future, where single-use derivatives are actively discouraged due to risk of drug resistance (as in this
case of ACTs in Appendix 3), complex hybrid solutions involving more combinations and reformulations and, ﬁnally,
cases where signiﬁcant increases in volumes will require additional capacity close to emerging markets. Combining such
criteria may also be used to identify clusters of candidate drug products with attractive business cases that may exhibit
similar areas of beneﬁt and scale for patients and government health service providers, made possible in the context of
adopting speciﬁc continuous processing technologies. This emerging ‘library’ of ‘product-process archetypes’ can inform
a classiﬁcation system that enables ease of comparability in identifying other drug candidates and new molecules that
may beneﬁt from speciﬁc technology interventions and opportunity areas.
Thirdly, in a future pharma context, it is argued that collaboration may be the key to success, but clear deliverables,
timelines and speciﬁc targets must be established to make alliances work. The management of AMT is not so straight-
forward in this scenario. Decisions on partner selection should involve not only assessing the type of AMT that is
Table 1. Barriers to the continuous manufacture of pharmaceutical drug products.
Barriers
Panel
size (N) ne
Content validity
ratio (CVR)
Social General belief is that continuous processing is only suitable for large volumes 15 5 −0.333
Lack of experience and fear of the unknown is delaying the implementation of
continuous technologies
15 9 0.2
Common view is that conversion, from current batch production equipment to
continuous production equipment, will not bring a good return on investment
15 8 0.067
Common misconception is that continuous processing is not ﬂexible 15 12 0.6
Uncertain market conditions/customer demands and shorter product life cycles are
key challenges for continuous manufacturing
15 11 0.467
Economic Resources required at the start-up of the continuous process and availability of
the equipment is a key consideration
15 8 0.067
Lack of ﬁnancial justiﬁcation for investment in continuous processing while
holding excess existing batch capacity (sunk cost and over capacity)
15 11 0.467
Specialised people or the up-skilling of current staff to control the continuous
process is required
15 9 0.2
Regulatory The existing regulatory system (or perception of it) is rigid and unfavourable to
the introduction of new innovative systems
15 6 −0.2
Lack of deﬁnition: If a continuous process is used within pharma, ‘batch size’
deﬁnition needs to be discussed and agreed with the regulatory authorities
15 8 0.067
Sterility is viewed as an issue as contaminants and by-products build up within
the system in a multi-product environment
15 8 0.067
Technological Losses that occur during start-up and shut-down periods, and control of such, is a
major challenge for continuous technologies
15 3 −0.6
Handling material that does not meet speciﬁcations is a major quality assurance
issue in continuous processing
15 8 0.067
Continuous technology is still more challenging in terms of crystallisation,
isolation, ﬁltration and drying
15 12 0.6
Solid formation, in general, can block reaction channels and it is currently
difﬁcult to overcome this problem
15 9 0.2
The challenge in micro and tube reactors is to make the reaction possible in solid
phase
15 9 0.2
Process Continuous manufacturing control systems constitute one of the major design
challenges
15 6 −0.2
Good online measurement tools (PAT and QbD systems) and integration between
the generated data and control software is challenging in a continuous context
15 8 0.067
Current batch processes must be fully understood before transferring to
continuous mode
15 3 −0.6
Implementing continuous processing requires a change in processes that have
already been validated
15 9 0.2
Process management and its execution (incorporating QC documents and
management) will be key factors when switching from batch to continuous
15 14 0.867
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appropriate for a particular manufacturing and business situation, but also its speciﬁcation, integration and use. Key
considerations from industry on ‘continuous capability and supplier development’ are as follows:
• Where are the ‘solution spaces’ (large volumes, elimination of working capital, speed of supply reducing
inventories and customising for the patient) where continuous processing can deliver value?
• What are the speciﬁc continuous AMT interventions, and associated technical challenges, that need to be over-
come to achieve delivery of these ‘solution spaces’?
It is suggested that the ideal supply chain may be composed of a mix of internal ﬁxed-capacity, with some degree
of external variable capacity. With a growing patient-centric focus and a move towards ‘outcomes-based’ business mod-
els, it is argued that future pharma may well be better served to focus on R&D and commercialisation, leaving emerging
CMOs to provide the ‘solution space’ or capacity to become an attractive ‘test-bed’ for rolling out new drug products.
There may be a requirement for more of a supplier development focus given that the industry needs to grow external
manufacturer capability to enable continuous manufacturing to develop. A critical counter argument here is increased
dependencies, especially external, may lead to suppliers of AMTs or input chemicals becoming future competitors as
they develop more core competencies in the focal ﬁrm’s key processes.
A fourth theme that emerged was whether the real opportunities for AMT adoption lay in ‘development’ stages. With
the transfer of many elements of clinical supply to commercial supply inherently built-in, should industry concentrate on
alternative clinical supply chain designs at an early phase, which may drive technology solutions to deliver precision,
speed, integration, inventory savings, increased ﬂexibility, improved product quality and quicker response to new customer
demands? This would involve a focus on speed-to-market for system or drug discovery, with commercial and ‘develop-
ment’ phases using continuous technologies to enable rapid synthesis and speed/efﬁciency as an optimal pathway to E2E
integration. The importance of continuous AMT implementation in ‘discovery’ could also enable rapidly shorter supply
chains where there may be less of a stability requirement for a ﬁnal drug product. This could open up potential opportuni-
ties for a new range of targeted molecules with a stability of a few weeks (i.e. radiopharmaceuticals).
Finally, while the adoption of speciﬁc AMTs in pharma may be used to serve existing markets more effectively, or
deliver unmet end-user needs, individual drug products may also be assessed, in the context of new continuous capabili-
ties and technology interventions that may create opportunities with respect to new and emerging markets. These could
include (a) drug products previously considered uneconomical to deliver via traditional batch processing routes, (b)
more established generic products which may need to ‘evolve’, in response to future trends and changing markets, in
addition to (c) new chemical entities for an initial assessment. High levels of investment in continuous AMTs may well
remove cost beneﬁts (initially), but once a maturity level is achieved and a technology is no longer proprietary but
widespread (like the example of laser printing), there will be opportunities for return on investment. However, continued
uncertainty with respect to timescales on certain continuous technology developments and implementation, versus
changing cost proﬁles of high cost and emerging countries remains a key concern for the sector.
7. Conclusions and future research agenda
Pharmaceutical organisations are now actively reviewing their global footprints and questioning whether they have the
optimal architecture and technologies for manufacturing in the future. In this study, we draw on a categorisation of
AMTs that may enable a shift from the traditional centralised and batch manufacturing paradigm of ‘make-to-stock’,
towards more re-distributed ‘continuous’ manufacturing operations and ‘make-to-order’ models. The research strategy
employed enabled an investigation of the scope, challenges and opportunities of speciﬁc AMT innovations, in the area
of continuous manufacturing and crystallisation, where current adoption rates within the pharmaceutical sector remain
low. This paper then presented new sources, in our study of AMT adoption in a global context – assessing the barriers
to implementation, and the pathways for delivering future continuous manufacturing scenarios – using a four-stage
assessment framework as a basis for data capture.
While our studies have highlighted a desire for improved integration, openness, collaboration and trust between
stakeholders, our ﬁndings also capture the high level of disparity in viewpoints that exist across the pharmaceutical
value network, emphasising the many uncertainties and transformational challenges that lay ahead. Secondly, the wide-
spread take-up of AMTs, in the area of ‘continuous’ manufacturing, is not solely dependent upon the technical require-
ments identiﬁed. Overcoming the barriers to adoption requires a coordinated and systematic approach to understanding
and quantifying the beneﬁts across the entire value network, in local and global contexts, in order to develop the
business case for the implementation of continuous AMT solutions.
In conducting this study, some limitations are evident which, however, present interesting opportunities for future
research. First, and inherent to the nature of emerging AMTs in Pharma, was access to a signiﬁcant number of case
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examples at this juncture. While the assessment framework was developed using an extensive literature review, testing
and reﬁnement was restricted to four workshops, with validation restricted to application using two in-depth case studies
to-date that were assessed by an expert panel. The second limitation of this study is a focus on small molecules, and on
solid oral dose forms. With the trend towards more biopharmaceuticals and more drug device combinations, future
research plans will include testing and reﬁning the framework using case studies involving other industry segments e.g.
macro-molecules, stratiﬁed medicines and extending the approach to health care contexts (e.g. medical devices and
digital e-health care technologies) – all of which will require some additional AMTs in process analytics, diagnostics,
and across the extended supply chain. These activities form part of an ongoing research agenda, as part of project
ReMediES (Re-conﬁguring Medicines E2E Supply), which explores
• Implications of digitalisation – from the perspective of AMT disruptions on traditional supply chains, solutions to
customise and address customer needs, and the effect on downstream supply chains to patient delivery.
• Development of ‘smart’ packaging AMTs, for security and anti-counterfeiting.
• Implications, in terms of AMT challenges in formulation, and the wider supply chain.
• The impact of regulatory trends, together with affordability and access to care/markets.
Several diverse pharmaceutical products have also been identiﬁed as part of this on-going study, in order to provide
the basis for exploring alternative product-process supply network options and value chain implications arising from a
technology intervention. These case studies were chosen as they represent products at different stages of their product
life cycle, have dissimilar product volume and pack complexity proﬁles, and varying transformation challenges if an
alternative process, value network and/or business case is implemented. In turn, this will inform a classiﬁcation system
(in development) that will enable ease of comparability to identify and connect drug product, AMT, and device, where
‘combinations’ of technologies may well beneﬁt from similar value network design and reconﬁguration opportunities.
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Six intervention points where research on the inkjet printing of pharmaceutical drug products will focus on
(adapted from Daly et al., 2015)
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Appendix 2.
Expert informants, by role, and their contribution to the 5 workshops
Workshop 1: Royal Society of Chemistry Symposium
Workshop 2: MIT Continuous Manufacturing Symposium
Workshop 3: Cambridge International Manufacturing Symposium
Workshop 4: Process technology applications and linkages
Workshop 5: Expert panel assessment
Interviewee/source Role/contribution area Organisation Workshop
1 Operations Director National Centre – Continuous
Manufacturing
1,2,4
2 Research Director, co-Principle Investigator, Pharma
Supply Chains
Academia (UK) 1,2,3,5
3 Senior Researcher, Chemistry Academia (UK) 1
4 Director of National Centre, Principle Investigator,
Pharmaceutical sciences
Academia (UK) 1,2,5
5 Head of Process Technology CMO – UK & India 1
6 R&D Chemical Engineer MNC – Global Pharma, health,
cosmetics
1
7 Director, Manufacturing projects CMO – Global Pharma R&D 1,4
8 Group Technical Director MNC – Global Process Engineering 1,2
9 Senior Project Engineer CMO – Petro-chemicals, food
processing
1
10 Manufacturing Technical Project Lead MNC – Global Pharma Manufacturing 1
11 Capability Lead for Clinical Operations MNC – Global Pharma Clinical Trials 1
12 Technology Lead, Continuous technologies MNC – Global Pharma Manufacturing 1
13 Senior Scientist MNC – Global R&D 1
14 Professor, Flow chemistry Academia (UK) 2
15 Director, Continuous technologies MNC – Global Pharma Manufacturing 2
16 Director, Advanced process analytics MNC – Global Pharma Manufacturing 2
17 Senior Researcher, Emerging technologies Academia (UK) 1,2,3,4,5
18 Professor, Global Manufacturing Academia (US) 3
19 Professor, Supply Chain Management Academia (US) 3
20 Researcher, Supply Chain Data Analytics Academia (UK) 3,4
21 Researcher, Policy and Standards Academia (UK) 3
22 Senior Researcher, Sustainable Operations Academia (EU) 3
23 Senior Researcher, Sustainability Academia (EU) 3
24 Senior Researcher, Supply Chains Academia (UK) 3
25 Former Head of Global Pharma Supply Chains Academia (UK) 3
26 Researcher, Sustainable Supply Chains Academia (UK) 3
27 Researcher, Supply Chain Design Academia (UK) 3
28 National Programme Advisor National Funding Body 4
29 Director of National Programme, Clinical Trials MNC – Global Pharma Clinical Trials 1,2,4
30 Technical Lead, API Manufacture National Centre – Continuous
Manufacturing
4
31 Technical Lead, Secondary Manufacture MNC – Global Pharma Manufacturing 4
32 Business Development and Technical Lead, CMO – Advanced Manufacturing
Technologies
4
33 Technical Lead, Pharma packaging MNC – Global Pharma Manufacturing 4
34 Project Lead, Smart packaging in Pharma National Centre – Process Industries 4
35 Technical Lead, Advanced ﬂow technologies MNC – Global Pharma Manufacturing 4
36 Technical Director, Process design SME – Process Industries 4
37 Project Manager, Innovation capability CMO – Global Process Engineering 4
38 Director, Continuous technologies CMO – Global Manufacturing
Development
4
39 Managing Director CMO – Intelligent Process Monitoring 4
40 Head of Strategy, Pharma and Life Sciences National Centre – Skills development 4
41 Product Manager, Continuous technologies CMO – Modular Equipment Design 4
(Continued)
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Appendix 2. (Continued)
Interviewee/source Role/contribution area Organisation Workshop
42 Managing Director CMO – Continuous Processing Systems 4
43 Business Development Manager, R&D CMO – Advanced Manufacturing
Technologies
4
44 Senior Engineer, Automation CMO – Customised Technical Solutions 4
45 R&D Team Lead MNC – Global Biopharma
Technologies
4
46 Operations Director CMO – Advanced Manufacturing
Technologies
4
47 Technical Director MNC – Global Biopharma
Technologies
4
48 Developer, Process systems SME – Advanced Process Modelling 4
49 Director, Business Development SME – Pharmaceutical Development
Services
4
50 Professor, Pharmacy and Biomedical Sciences Academia (UK) 5
51 Professor, Chemical and Process Engineering Academia (UK) 5
52 Professor, Chemical Engineering Academia (UK) 5
53 Research Fellow, Chemistry Academia (UK) 5
54 Research Fellow, Process Engineering Academia (UK) 5
55 Research Fellow, Chemical Engineering Academia (UK) 5
56 Manufacturing Fellow, Chemistry and Process Academia (UK) 5
57 Senior Lecturer, Modelling Academia (UK) 5
58 Researcher, Medicinal Chemistry Academia (UK) 5
Appendix 3:
Four-stage framework, with case study example, to assess the feasibility of adopting continuous manufacturing
technologies for the production of pharmaceutical drug products
Stage Step Description
Case study example – Global supply of Artemisinin-based
combination therapies (ACTs)
1 Gather basic data on drug candidate (e.g.
Therapy Area, Patient Population, Treatment
proﬁle(s) Cost, Volumes)
Therapy/disease area: Malaria; Patient population (global
context): 104 countries; Treatment proﬁle: currently 220 M
cases, with an estimated 280 M treatments per annum;
Dosage: Medium-High (Coatrem-24 tablets; dose is 4
tablets); Frequency: Full course of treatment is 6 doses of
Coartem, taken over 3 days); Duration: 7–14 days; Other:
Diagnostic test required; Volumes: 200 tonnes/annum
(current); Cost of API: $500–600/kg (plant-derived), $350–
400/kg (biosynthetic route); Strengths: Coatrem: ﬁxed at
20 mg Artemisinin; 120 mg of Lumefantrine; Pack sizes:
12 and 24.
Pre-screening 2 Rapid opportunity/barrier analysis (e.g.
operational and societal data)
Overview: ACTs remain the ﬁrst-line response for the
treatment of malaria. There were 660,000 deaths in 2011.
Eighty per cent of deaths occured in just 17 countries, the
majority of which have household incomes of less than
$1.25 per person per day. Intent is to reduce treatment cost
to circa $0.50 per dose. Timescale yet to be deﬁned.
Funding: To address a lack of funding, the Global Fund, in
partnership with the UN, WHO and World Bank have
created the Affordable Facility for Manufacturing – malaria
(AMFm), as a vehicle to provide ﬁnancial subsidies for
qualiﬁed commercial treatment products to qualifying
countries. Global funding for malaria prevention and
(Continued)
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Appendix 3. (Continued)
Stage Step Description
Case study example – Global supply of Artemisinin-based
combination therapies (ACTs)
treatment was US$2.3B (in 2011), which is still less than
required to support WHO goals.
Treatment proﬁle: Diagnostics tests are required to conﬁrm
malaria and source of infection. This represents the most
signiﬁcant cost in treatment (over $4 per patent). Due to
the cost and potential delay, most fever is treated
presumptively (i.e. an anti-malarial is given as a precaution
– estimated at 60 M treatments in 2011).
Quality assurance: It has been estimated that only around
59% of malaria cases are treated with quality ACT, with
implications for demand. Counterfeits are prevalent in
many countries leading to high risk and mortality.
3 Rapid volume/variety analysis (e.g. future
predicted volumes and SKU counts)
Volumes: From 200 tonnes to 300 tonnes/annum (future).
Currently, it is estimated that 10,000 sites are producing
60,000 metric tonnes of raw material, very low yields.
SKUs/Variety: Future requirement to develop more
combinations as use of a single Artemisinin derivative is
actively discouraged due to risk of drug resistance. ACT
derivatives have also shown utility in treating other
diseases, such as cancers, but this has had limited clinical
development to-date.
4 Unmet needs (e.g. business context) Future costs: AMFm is sustainable at country level under
the conditions that the subsidy level for ACTs remains at
its current level (approximately 92%) and that prices of
ACTs do not increase during the ﬁve-year period of
interest (2013–2017); Diagnostics tests required to conﬁrm
malaria and source of infection represent the most
signiﬁcant cost in treatment (> $4 per patient).
5 Process chemistry (e.g. is the ‘process’ pre-
disposed to Continuous manufacturing?)
Opportunity as current chemical synthesis (batch route) is
difﬁcult and expensive, due to the complex nature of the
molecule. (Criteria assessed here includes: molecule;
polymorph; chirality; number of process steps; particle
engineering; kinetics; stability; bioavailability; ﬁnal dosage
form and ease of scale-up/scale-out).
6 Critical Review & Opportunity Scoping – Gate 1 High potential – value network reconﬁguration
opportunities end-2-end (E2E) in adopting continuous
manufacturing technologies, in developing diagnostics, and
in implementing ‘smart’ anti-counterfeiting packaging.
Current State
process
mapping
1 Application of supply network conﬁguration
tools (in speciﬁc contexts)
Current global manufacturing footprint: 16 × Artemisinin
producers – China (8) Vietnam (5) Kenya (1) Uganda (1)
Madagascar (1); 10 × WHO Prequaliﬁed API
Manufacturers – India (6) China (3) Italy (1); 12 × WHO/
EMA Prequaliﬁed ACT Manufacturers – India (6)
Germany (2) Italy (1).
2 Current state analysis (sub-systems) The overall lead time from crop planting to ﬁnal product
shipment is approximately 14 months, and highly variable
(being impacted by weather and local economic factors)
and, is expensive compared to the target treatment cost.
There is also a large variation in Artemisinin content in the
leaves of plants from different origins and regions.(Criteria
assessed here examines potential for impact by technology
interventions across sub-systems e.g. clinical trials, primary
and secondary manufacturing, packaging and E2E supply).
3 Populate Opportunity Grid (assessment versus 15
impact variables)
Identifying the potential beneﬁts using a continuous
manufacturing technology intervention outcomes matrix
shows potential for improved quality and supply reliability,
and a reduction in overall product cost.
4 Current state ﬂow chart (e.g. current process
technology in use)
Plant extraction/puriﬁcation and multi-stage batch (Focus
on synthesis; puriﬁcation; isolation; formulation;
packaging).
5 Critical Review & Opportunity Scoping – Gate 2 High potential – continuous technology ‘interventions’,
from synthesis right through to packaging and labelling, to
be considered in developing and assessing a series of
alternative supply models.
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Appendix 3. (Continued)
Stage Step Description
Case study example – Global supply of
Artemisinin-based combination therapies (ACTs)
Future state model(s) 1 Sub-systems (clinical trials, primary and
secondary manufacturing, packaging and E2E
supply) – future state analysis
Alternative continuous manufacturing route derived
with the aim of reducing overall process lead-time
from an estimated 30–90 days (currently) to
5–10 days. Future scenarios developed as part of a
current-future state analysis, namely:
A: Reformulate in order to increase
bioavailability. Potential here to reduce the
‘dosage’, hence, volumes required for a
series of new formulation(s).
B: Develop more combinations for ACTs due
to risk of drug resistance
C: Hybrid solution involving more ACT
combinations and reformulations
D: Volumes set to increase dramatically, with
opportunities in other therapy areas
2 Explore Continuous manufacturing technology
options (leveraging latest experimentation data
and/or literature)
3 Generate alternative process and supply
network design option(s)
4 Expert Panel Assessment High potential – opportunities to reduce cycle times
and inventory, by adopting continuous processes that
also reduce solvent use. Several technology
developments are considered with maturing
technology readiness levels, which suggest promising
routes to commercialisation and adoption.
Case for adopting
speciﬁc
technology
intervention(s)
1 Assessment Framework Output (current state
vs. future state(s))
Currently, there is a lack of transparency in the
supply chain hampered by inaccurate and untimely
country demand forecasts. Opportunities to
signiﬁcantly reduce lead-time and increase service
levels.
2 Business Context/Viability Currently, a fragmented extraction and manufacturing
market with high transaction costs. Potential for cost
and inventory reduction.
3 Technology Readiness Several continuous schemes have been developed
which demonstrate potential feasibility and beneﬁts.
4 Develop case for transformation dossier High potential – in adopting manufacturing scenario
A, initial projections suggest potential to reduce
product cost to around 60% of current prices, and the
treatment adherence burden in a relatively short time
frame (compared, say, to a new drug combination)
thereby maximising the impact beneﬁt for patients
and society.
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